Background: Dexamethasone, cytarabine (ara-C), and cisplatin (DHAP) can be used effectively to treat patients with nonHodgkin's lymphoma (NHL). We hypothesized that substitution of cisplatin by oxaliplatin (L-OHP) could result in less toxicity and greater efficacy. L-OHP is active in patients with lymphoma. It produces mild myelosuppression and is devoid of renal toxicity. We report on a phase II study of dexamethasone, high-dose ara-C, and L-OHP (DHAOX) used to treat patients with NHL who were previously treated with chemo-
Summary
Background: Dexamethasone, cytarabine (ara-C), and cisplatin (DHAP) can be used effectively to treat patients with nonHodgkin's lymphoma (NHL). We hypothesized that substitution of cisplatin by oxaliplatin (L-OHP) could result in less toxicity and greater efficacy. L-OHP is active in patients with lymphoma. It produces mild myelosuppression and is devoid of renal toxicity. We report on a phase II study of dexamethasone, high-dose ara-C, and L-OHP (DHAOX) used to treat patients with NHL who were previously treated with chemotherapy.
Patients and methods: Fifteen patients were given DHAOx. They had failed to achieve a CR with initial chemotherapy or had recurrent disease. DHAOx consisted of dexamethasone, 40 mg/day (days 1 to 4); L-OHP, 130 mg/m 2 (day 1); and ara-C, 2000 mg/m 2 every 12 h (day 2). Treatment was repeated every 21 days.
Results' Patients received a median of four courses of DHAOx. Myelosuppression and transient sensory peripheral neuropathy were the most prominent toxic effects. Serum creatinine levels did not increase in patients with normal renal function, nor in patients who had renal impairment before DHAOx. The median follow-up time from the start of DHAOx treatment was 17 months. Eight patients (53%) achieved a CR. and three patients (20%) had a PR. Responses were achieved by patients with lymphomas of various histologies that included mainly the follicular subtype, and by patients with and without resistance to prior chemotherapy. None of the eight responders have relapsed from CR at 4+, 6+, 14+, 15+. 19+, 20+, 24+, and 24+ months. They had various types of therapy after DHAOx. Disappearance of molecular markers was observed in all four patients who achieved a CR and whose tumor cells carried molecular abnormalities.
Introduction
Regimens of chemotherapy used as salvage treatments for patients with non-Hodgkin's lymphoma are available only in limited numbers. One of these regimens is DHAP, which consists of dexamethasone, high-dose cytarabine (ara-C), and cisplatin [1] [2] [3] [4] . The efficacy of DHAP is remarkably high. However, it produces severe myelosuppression, peripheral neuropathy, and frequent renal toxicity that often requires discontinuation of the treatment.
Based on laboratory and previously reported clinical data, we hypothesized that substitution of cisplatin by oxaliplatin, [trans-(L)-l,2-diaminocyclohexane] oxalatoplatinum (II) (L-OHP), in the DHAP schema could result in lower toxicity and, perhaps, greater efficacy.
L-OHP is a platinum coordination complex with an oxalato ligand as the leaving group and a 1,2-diaminocyclohexane carrier. The drug possesses activity against a number of human and murine tumor cells in vitro and in vivo, including murine leukemia cell lines [5, 6] . It has a higher cytotoxic potency on a molar basis than do cisplatin and paraplatin, and it is active on various cell lines that have been selected for resistance to cisplalin. The drug used as a single agent is active in several types of solid tumors [7] , and it was reported to achieve responses, mostly partial, in 40% of patients with nonHodgkin's lymphomas of various histologic types [8] . Toxic effects of oxaliplatin include dose-related peripheral neuropathy, vomiting, diarrhea, and mild myelosuppression. The drug is devoid of renal toxicity [7] .
We designed a regimen of dexamethasone, high-dose ara-C, and L-OH P (DH AOx) to be used in the treatment of patients with NHL who required salvage treatment, i.e., who failed to achieve a complete response with CHOP or CHOP-derived chemotherapy regimens, had recurrent disease, or suffered from visceral damage leading to increased risk of toxicity preventing the use of regimens including anthracyclines and/or nephrotoxic cytostatic agents. We now present the results of a phase II study of DHAOx for induction treatment of patients with non-Hodgkin's lymphoma who were previously treated with chemotherapy.
Patients and methods

Patients
Each patient was required to have a previously diagnosed non-Hodgkin's lymphoma that could be measured clinically and /or by CTscan (Table I) The hislologic types were defined according to the Revised European American Lymphoma (R.E.A.L.) Classification [9] . For inclusion in the study, patients had either to have failed to achieve a CR with the initial induction chemotherapy or to be in relapse. They had to have been treated with at least one CHOP or CHOP-derived. adriamycin-containing regimen. Relapsing patients could have been either previously untreated or treated with chemotherapy for their relapse. Two categories of patients were defined according to their Fifteen patients were included in the study; all were evaluable for response to therapy (Table I) . Patients were at a median of 21 months from diagnosis (range, 1-130 months). All of the patients were considered to be unable to attain a long-term benefit with any currently available front-line or salvage regimen of therapy Treatment was administered to consecutive patients on a compassionate-need individual basis over a 2.5-year period. Oral informed consent was obtained from each patient. The study was conducted in a single institution.
Treatment protocol
DHAOx consisted of dexamethasone, 40 mg/day i.v. from day I to day 4: L-OHP (Debiopharm S.A.. Lausanne. Switzerland, and SanofiSynthelabo, Paris, France), 130 mg/m 2 infused i.v. over 2 hr on day 1 as previously described [7] . and ara-C. 2000 mg/m 2 infused i.v. over 3 h every 12 h on day 2. Granulocyte-colony stimulating factor (G-CSF) at a dose of 5 ug/kg/day was administered from day 3 until recovery of PMN counts to above 500 PMN/ul. Patients did not receive any prehydration. Treatment was repeated every 21 days. The dose of L-OHP was reduced by 30 mg/m 2 in subsequent courses in cases of grades 1-2 peripheral neuropathy according to the scale presented in Table 2 . Treatment was stopped when a response could not be attained after three courses of therapy, and at any time in cases of peripheral neuropathy of grades >3. In responding patients, courses of DHAOx were repeated until CR was attained. Patients in CR were considered for intensive chemotherapy followed by autologous stem-cell transplantation, and attempts were made at collecting their peripheral blood stem cells (PBSCs) by cytapheresis. Complete responders who could not be treated with intensive post-induction chemotherapy, and patients who did not achieve a CR with DHAOx. were subsequently 
Assessment of response to therapy
A complete tumor assessment was obtained prior to entry into the study. This was repeated after three consecutive courses of therapy, and every three months after completion of treatment. Tumor dimensions were measured clinically and by CTscan. Bone marrow biopsies were repeated for assessment of response if bone marrow was involved by lymphoma before treatment. Complete response was defined by the complete disappearance of all clinical and radiographic evidence of disease and of all disease-related symptoms, and normalization of the biochemical abnormalities assignable to the lymphoma. If the bone marrow was involved, the infiltrate had to be cleared at the time of any subsequent bone marrow biopsy. Partial response required a >50% reduction of the sum of the products of the two longest orthogonal diameters of all lymph node masses and visceral nodules, with no sign of tumor progression at any site. To be accepted as such, CRs and PRs had to be established in two consecutive tumor assessments performed at least one month apart. Stable disease was considered when tumor regression was less than that required for a PR, and progressive disease was defined by an increase by ^25% of the sum of the products of the two longest orthogonal diameters of any previously identified abnormal lymph node or visceral involvement, or by the appearance of any new lesion [10] .
Assessment of molecular markers
Assessments of genetic molecular markers were chosen according to the lymphoma histologic subtypes. Samples were initially obtained from lymph nodes, bone marrow, peripheral blood, and, in selected cases, from other organs involved with lymphoma. Assays included (a) PCR amplification of the rearranged VH-J H region of the immunoglobulin heavy chain genes [11] , and of the rearranged Vy-J Y region of the TCRy genes [12] , followed by size analyses of products, for determination of B-and T-cell clonahty, respectively; and (b) PCR amplification of the BCL2-IgH fusion gene (MBR and mcr) which results from the t(14;18) in B-cell lymphomas [13] , and of the BCLl-IgH fusion gene from the t(ll;l4) in mantle cell lymphoma [14] After treatment with DHAOx, molecular markers were assessed in peripheral blood and bone marrow in parallel with the evaluation of response to therapy In patients whose PBSCs were collected, molecular assays were performed in samples of cytapheresis-harvested cells before autologous transplantation.
Results
Toxic effects
The 15 patients received a total of 60 courses of DHAOx (range, 1-8 courses per patient; median, 4 courses) which were evaluated for toxicity ( Table 2 ). The median cumulative dose of L-OHP given to patients during the study was 400 mg/m 2 (range, 130-1040 mg/m 2 ). Myelosuppression was the most prominent toxic effect. Grades 3 and 4 granulocytopenia were experienced by 33% and 33% of patients, respectively. Episodes of granulocytopenia were of short duration with G-CSF support, and no patient developed an infectious complication. Grade 3 thrombocytopenia occurred in 13% of patients, and grade 4 thrombocytopenia was a toxic effect in 73%, requiring occasional platelet transfusions. Grades 2 and 3 anemia occurred in 47% and 13% of the patients, respectively.
Two patients had sensory peripheral neuropathy before their inclusion in the present study. Of these, one had prior exposure to cisplatin, and in the second the cause of the neuropathy was unknown. Therefore, only 13 patients could be evaluated for neuropathy after treatment with DHAOx. Transient sensory peripheral neuropathy was observed in 46% of the patients. Grades (Table 2 ) were 1 in 31% of patients and 2 in 15% of the patients. Grades ^ 3 were not observed during this study. No late signs of neuropathy appeared during the follow-up period. For patients with preexisting peripheral neuropathy, treatment with DHAOx did not aggravate symptoms.
No increase in serum creatinine levels above the normal range was observed in patients with normal renal function. Two patients had previous renal insufficiency. One patient had had renal infiltration by the lymphoma, and the second had renal damage due to prior exposure to cisplatin. None of the two patients with renal insufficiency before DHAOx suffered any worsening of their renal function after the treatment. Diarrhea was not recorded as a toxic effect during this study.
Response to therapy
The median follow-up time for the 15 patients from initiation of DHAOx was 17 months (range, 1-30 months). Eleven patients (73%) attained a response (Table 3) . Eight patients (53%) achieved a CR, and three patients (20%) had a PR. Four patients (27%) failed to respond. The median time required for patients to achieve a response was nine weeks (range, 4-15 weeks). None of the eight complete responders has relapsed at the time of the present report. They had various types of post-induction therapy after DHAOx, which consisted in intensive chemotherapy followed by autologous peripheral blood stem cell transplantation in four patients whose PBSCs could be mobilized and collected; a interferon was given to three patients, and rituximab to two patients; their disease-free survival times were 4+, 6+, 14+, 15+, 19+, 20+, 24+, and 24+ months. Times to disease progression for partial responders were 3+, 4+ months, and 14 months. Of the four complete responders who did not have their PBSCs collected, one patient refused to be treated with intensive post-induction chemotherapy, and three patients could not have their PBSCs successfully mobilized. These patients had received ^ 3 different regimens of chemotherapy before their inclusion in the present study. Great amounts of chemotherapy prior to DHAOx may well have been the cause of failure of the mobilization process.
Most of the histologic types included in this study responded to DHAOx. These consisted in lymphomas of follicular, marginal zone B-cell, hepatosplenic y/ § T-cell, anaplastic large T-cell, and diffuse large B-cell types. Responses were achieved by patients with and [9] without demonstrated resistance to prior chemotherapy (Table 3 ). All patients had been treated with at least one prior regimen of therapy (median, 2; range, 1-7 regimens).
Molecular marker follow-up
Disappearance of molecular markers in tissues that were initially infiltrated with lymphoma was observed in all four patients who achieved a CR with DHAOx, and whose tumor cells carried abnormalities (Table 4) . Furthermore, in none of the three patients with molecular markers who attained a CR with DHAOx and had their PBSCs collected, could residual markers be detected in cytapheresis-harvested cells.
Discussion
The present study demonstrates that DHAOx possesses great activity in patients with non-Hodgkin's lymphoma who had received prior treatment. Seventy-three percent of the patients responded to therapy, and 53% attained a CR with DHAOx. Overall response rates ranging from 55% to 67%, including CR rates ranging from 15% to 31%, have been reported previously with DHAP in series of patients with various types of non-Hodgkin's lymphoma who were previously treated with chemotherapy [1] [2] [3] [4] . These studies included mostly patients with aggressive high-grade lymphomas. In the present study, we observed responses in patients with lymphomas of various histologies that included mainly the follicular type. Responses were also achieved by patients with aggressive lymphoma subtypes. However, of the four patients with diffuse large B-cell lymphoma, only one attained a PR. Large clinical trials are necessary to demonstrate that differences in response rates between studies with DHAP [1] [2] [3] [4] and those observed in the present study are due to an imbalance in numbers of patients with the various subtypes of lymphoma.
The DHAP regimen is based on the demonstrated synergism between cisplatin and cytarabine [15] . Although experimental data for a synergistic interaction between ara-C and L-OHP are not available, the activity observed in this study suggests that synergy might occur as well with DHAOx.
Patients who attained a CR, and whose tumor cells carried molecular tumor markers, had disappearance of these markers in tissues where they were found to be present prior to treatment. Moreover, molecular tumor markers were absent in the cytapheresis-harvested cells of the complete responders whose PBSCs were collected. These sensitive methods for detection of minimal residual disease were not used as response criteria per se. However, they are indicators for the level of tumor mass " According to the R.E.A.L. Classification [9] , b Assays for molecular markers were performed in peripheral blood and bone marrow in all cases. Before initiation of treatment with DHAOx. the bone marrow was infiltrated with tumor cells in all cases as proved histologically. and molecular abnormalities were detected in the bone marrow or in both peripheral blood and bone marrow. c Molecular markers were assessed in peripheral blood and bone marrow in all cases. d Included detection of the BCL2-lgH fusion gene (MBR and mcr). and of the rearranged VH-J H region of the lmmunoglobulin heavy chain genes. " Detection of the BCLl-lgH fusion gene. ' Detection of the rearranged Vgamma-J gllmma region of theTCRy genes. 8 Molecular markers were also assessed in the liver. reduction achieved with DHAOx in complete responders, a fact that has important implications for the outcome in the long term [16, 17] .
Toxicity was within acceptable limits of tolerance. High degrees of granulocytopenia and thrombocytopenia occurred in 66%, and in 87% of patients, respectively. However, they were of short duration, did not require hospitalization, and did not result in complications. The planned time interval between courses could be maintained after each course of DHAOx.
The dose-limiting toxic effect of oxaliplatin is sensory peripheral neuropathy, the incidence and severity of which rise with increasing cumulative amounts of the drug [7] . In this series, transient peripheral neuropathy was experienced by 46% of the assessable patients. Neuropathy of grades ^ 3 was not observed in the present study, during which patients had received doses of L-OHP ranging from 130 to 1040 mg/m 2 , and a median dose of only 400 mg/m 2 . Larger cumulative doses and greater numbers of patients are required for a more precise evaluation of this toxic effect. Comparisons with data from prior clinical trials [7] did not indicate that the combination of L-OHP with high-dose ara-C altered the incidence or the characteristics of L-OHP-related sensory neuropathy.
The toxicity profile of DHAOx allowed treatment to be given to patients with moderate degrees of renal insufficiency without any worsening of their preexisting condition. In the absence of prehydration, episodes of fluid overload were not observed in patients with decreased left ventricular ejection fraction or overt congestive heart failure due to prior treatment with adriamycin. No patient had therapy discontinued because of toxic effects of the treatment.
The present results demonstrate that DHAOx is highly active for treatment of patients with non-Hodgkin's lymphomas who had been treated previously, and possesses toxicity characteristics which compare favorably to those reported with DHAP. DHAOx may be used as salvage treatment for patients with these diseases. Larger phase II studies are required for establishing the therapeutic potential of the present regimen.
